PolyPid Ltd
NASDAQ:PYPD

Watchlist Manager
PolyPid Ltd Logo
PolyPid Ltd
NASDAQ:PYPD
Watchlist
Price: 3.45 USD 0.58% Market Closed
Market Cap: 35.2m USD

EV/EBITDA
Enterprise Value to EBITDA

-1
Current
-0.5
Median
13.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-1
=
Enterprise Value
27.5m USD
/
EBITDA
-27.7m USD
EBITDA Growth EV/EBITDA to Growth
IL
PolyPid Ltd
NASDAQ:PYPD
Average EV/EBITDA: 434
Negative Multiple: -1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
28.4
30%
0.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
14.3
8%
1.8
CH
Roche Holding AG
SIX:ROG
9.2
5%
1.8
UK
AstraZeneca PLC
LSE:AZN
113.4
10%
11.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
13%
0.8
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
US
Merck & Co Inc
NYSE:MRK
8.3
7%
1.2
IE
E
Endo International PLC
LSE:0Y5F
291.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.7

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-1.2
2-Years Forward
EV/EBITDA
-1.6
3-Years Forward
EV/EBITDA
N/A